Format

Send to

Choose Destination
Hepatol Int. 2010 Jul 29;4(3):641-8. doi: 10.1007/s12072-010-9196-0.

Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis).

Author information

1
Institute of Immunology, Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027 China.

Abstract

PURPOSE:

Concanavalin A (Con A)-induced hepatitis is an extensively used animal model of T cell-mediated acute hepatitis. A variety of cytokines, including interleukin 4 (IL-4), interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α), have been shown to play important roles in Con A-induced liver injury. However, the role of IL-2, a critical cytokine in the development and function of T cells and a clinical therapeutics for virus infection and tumor, has not been carefully examined in this model.

METHODS:

In this study, we investigated the function of IL-2 in Con A-induced hepatitis by using various strategies of rhIL-2 pretreatment. We treated mice with two rhIL-2 administration strategies: a single injection of high dose of rhIL-2 (IL-2(hi), 50 × 10(3) U/mouse) and four injections of low dose of rhIL-2 (IL-2(4lo), 5 × 10(3) U/mouse).

RESULTS:

IL-2(hi) pretreatment ameliorated Con A-induced liver injury, while IL-2(4lo) aggravated Con A-induced liver injury. IL-2(hi) pretreatment reduced Con A-induced elevation of serum TNF-α while IL-2(4lo) pretreatment did not. Serum IL-4 and TNF-α were high 6 h after Con A injection in IL-2(4lo) mice, while it was undetectable in IL-2(hi) and non-pretreated mice. IL-2(hi) pretreatment reduced Con A-induced accumulation of T cells in liver while IL-2(4lo) pretreatment increased accumulation of NK cells.

CONCLUSION:

Various strategies of rhIL-2 administration play different roles in Con A-induced hepatitis, suggesting the importance of IL-2 administrative regime in clinical liver diseases.

KEYWORDS:

Concanavalin A; Hepatitis; Interleukin 2

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center